Compound shows potential to treat Gleevec-resistant patients.

SymBio Pharmaceuticals obtained rights to a drug that’s touted to have therapeutic potential to treat Gleevec-resistant chronic myeloid leukemia and mast cell leukemia.


PEG-ZnPP was developed by Hiroshi Maeda and fellow researchers at Sojo University. According to Maeda, PEG-ZnPP exhibits an inhibitory antitumor effect on heme oxygenase activity, leading to an increase in the production of toxic oxidants and eventual cancer cell death.


This exclusive global license adds a third clinical candidation to SymBio’s pipeline.

Previous articleCisbio Strengthens HTRF Portfolio with Lumiphore’s Fluorescent Lanthanide Detection Reagents
Next articleMechanism for Gene Expression Change Associated with Addictive Drugs Revealed